Table 4.

Haloperidol or Risperidone and risk of all-cause mortality

Study Name	HR	Lower 95% CI	Upper 95% CI	Drug use/days
A. Haloperidol current users relative to non-users or users of other drugs.
Langballe	2.938	2.324	3.714	0–180
Martin-Arias*	2.710	1.980	3.690	Proportional Reporting Ratios
Jones¥	2.330	2.120	2.560	0–30 days
Rossom	2.300	1.600	3.300	0–30 days
>1 mg/ day	3.20	2.20	4.50	0–30 days
Maust	2.457	2.070	2.916	0–180 days
D-L Random Model	2.427	2.254	2.614	0–180 days
B. Haloperidol relative to Risperidone as reference (HR = 1).
Kale 2012	2.24	n.d.	n.d.	0–30 days
	1.59	1.36	1.85	30–180
Huybrechts 2012	2.07	1.89	2.26	0–180
Langballe	1.700	1.00	3.00	0–30
	2.007	1.464	2.751	180–365
Koponen ≤ 1 mg/day	1.66	1.10	2.50	0–180
>1 mg/day	2.55	1.70	3.85	0–180
Liperoti 2009	1.383	1.240	1.543	0–180
D-L Random Model	1.711	1.408	2.079	0–180
C. Risperidone HR relative to non-users.
Langballe	1.976	1.504	2.595	0-180 days
Piersanti 2014	2.112	1.152	3.871	Average use 7 months, follow-up to 3 years
Jones 2013	1.640	1.56	1.72	0–30 days
Maust 2015	1.641	1.483	1.816	0–180 days
Martin-Arias*	2.07	1.56	2.75	Proportional Reporting Ratio
Koponen 2017	1.428	1.336	1.525	0–180 days
D-L Random Model	1.647	1.496	1.813	0–180 days
D. Risk of All-Cause Mortality from Antipsychotic drug use in the General User Population.
Ray FGA	1.99	1.68	2.34	44,218 users
Jennum FGA	2.026	2.016	2.036	138/32,606
Jones FGA	2.34	2.28	2.41	15473
D-L Random Model	2.132	1.887	2.409
Ray SGA	2.26	1.88	2.72	46,089
Jennum SGA	1.785	1.779	1.791	222/32606
Jones SGA	1.76	1.71	1.82	7356
D-L Random Model	1.788	1.728	1.851

^¥Antipsychotic users (incl. 13.7% dementia) compared to psychiatric non-users (24% dementia). ^*All users, including dementia patients.